克拉斯
医学
癌症研究
结直肠癌
癌症
抗性(生态学)
化学
内科学
生物
生态学
作者
Mark M. Awad,Shengwu Liu,Igor I. Rybkin,Kathryn C. Arbour,Julien Dilly,Viola W. Zhu,Melissa L. Johnson,Rebecca S. Heist,Tejas Patil,Gregory J. Riely,Joseph O. Jacobson,Xiaoping Yang,Nicole S. Persky,David E. Root,Kristen E. Lowder,Hanrong Feng,Shannon Zhang,Kevin M. Haigis,Yin P. Hung,Lynette M. Sholl
标识
DOI:10.1056/nejmoa2105281
摘要
Clinical trials of the KRAS inhibitors adagrasib and sotorasib have shown promising activity in cancers harboring KRAS glycine-to-cysteine amino acid substitutions at codon 12 (KRAS
科研通智能强力驱动
Strongly Powered by AbleSci AI